Login to Your Account

Financings Roundup

Shopping Spree Due for Onyx? $310M Opens 'Any-Stage' Door

By Jennifer Boggs

Monday, August 10, 2009
Concurrent offerings of stock and convertible notes are expected to bring Onyx Pharmaceuticals Inc. as much as $310.3 million in net proceeds - $356.9 million if underwriters opt to buy more shares and notes - as the firm looks to expand its pipeline offerings beyond the cancer drug partnered with Bayer HealthCare Pharmaceuticals Corp. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription